Effectiveness of Treatments for Long Vax: Protocol for a Prospective Cohort Study (Preprint) DOI Creative Commons
Matthew Halma

Опубликована: Дек. 19, 2024

BACKGROUND Research efforts focusing on long covid have so far produced insights into the dysregulation of body processes. Development therapeutics has been limited to a few options which largely panned out. However, research work found some useful relationships between different diseases, and one important finding lends itself subsequent therapeutic are metabolic discoveries in patients. OBJECTIVE This study aims determine effective treatment for patients presenting with post vaccination syndrome, find biomarkers most predictive disease severity. METHODS Patients syndrome will be tested at baseline their general health (PAC-19QoL inventory, 6 Minute Walk Test Heart Rate Variability), prevalence spike protein, inflammatory markers (High sensitivity C-reactive Tumour necrosis factor alpha, IL-6, Antinuclear Antibody), as well coagulation (Von Willebrand Factor D-Dimer), (Acylcarnitine profile, free fatty acids, Hemoglobin A1c, β-Hydroxybutyrate, uric acid, amino acid panel, oxidation percentage, post-exercise lactate). also asked get commercial whole genome sequence identify risk loci vaccine injury or any interactions protocols. take combined nutraceutical supplement daily three months. Biomarker measurements taken interim after months assess non-inferiority control group. RESULTS is trial protocol, results analyzed see if there difference parameters follow up performed 1.5 trial, 3 following protocol. CONCLUSIONS The novel entity ‘long vax’, shares similar etiology features Covid, class protein related diseases (SPRD), high priority addresses an underserved patient population. While suggested levels evidence, from mechanistic hypothesis, vitro data, clinical trials conditions (acute Covid-19 infection), very exist vax. Our evaluate effectiveness protocol CLINICALTRIAL registered clinicaltrials.gov.

Язык: Английский

An updated review on the phytochemistry and pharmacological activity of black cumin (Nigella sativa L.) DOI Creative Commons
Raghvendra Pandey, Brijesh Pandey, Atul Bhargava

и другие.

Advanced Chinese Medicine, Год журнала: 2025, Номер unknown

Опубликована: Март 23, 2025

Abstract In this review, a comprehensive and systematic evaluation of the phytochemical constituents, traditional medicinal applications, current pharmacological research, toxicity, nanobiotechnology black cumin has been undertaken. An exhaustive database retrieval was conducted to collect scientific information about Nigella sativa L. from 1956 2025 using PubMed, Scopus, ISI Web Science, SciFinder, CABI. Search carried out keywords “ ,” oil,” “Ethnobotany,” “Phytochemistry,” “Pharmacological activity,” “Toxicity,” “Nanotechnology.” Several important phytochemicals are found in seeds N . L., many which seem have good impact on human health put use Ayurvedic, Unani, Siddha systems medicine. Among active compounds, thymoquinone is most important, forming 30%–48% oil fraction. Besides thymoquinone, wide range such as thymohydroquinone, dithymoquinone, p ‐cymene, sabinene, carvacrol, 4‐terpineol, kaempferol (glucoside) t ‐anethol, longifolene (sesquiterpene), α ‐pinene, ‐hederin (pentacyclic triterpene), thymol also reported. Current research provided evidence for uses cumin, especially antioxidant, anti‐inflammatory, antibacterial, antifungal, antiviral, anticancer, antidiabetic, neuroprotective, gastroprotective, antiarthritic effects. The review provides an in‐depth analysis phytochemistry, well potential properties Since plant being extensively investigated its properties, valuable up‐to‐date status will act reference future applications plant.

Язык: Английский

Процитировано

0
Nigella sativa for the treatment of COVID‐19 patients: A rapid systematic review and meta‐analysis of randomized controlled trials DOI Creative Commons
Mohammad Umer, Aiman Naveed,

Qanita Maryam

и другие.

Food Science & Nutrition, Год журнала: 2023, Номер 12(3), С. 2061 - 2067

Опубликована: Дек. 27, 2023

Abstract Nigella sativa is an herbal therapy for various afflictions. It has some potential to be a promising option as efficacious treatment COVID‐19 patients that can contribute global healthcare relatively cheap but evidence of its use from randomized controlled trials (RCTs) limited. Therefore, explore the effect N. in combating COVID‐19, we undertook this meta‐analysis. We searched several databases retrieve all RCTs investigating compared placebo or standard care. used RevMan 5.4 analyses with risk ratio (RR) odds (OR) measures. included total seven review. significantly reduced all‐cause mortality control group (RR 0.27, 95% CI: 0.10 0.72; I 2 = 0%). rate viral PCR positivity 0.62, 0.39 0.97; did not find any significant difference hospitalization 0.26, 0.04 1.54; 0%) and no recovery (OR 0.48, 0.20 1.15; 84%) between two groups. easily available medicine may decrease improve virological clearance patients. However, our results are limited by small number available. Further large‐scale needed better understand anti‐inflammatory antiviral effects

Язык: Английский

Процитировано

3
Effectiveness of Treatments for Long Vax: Protocol for a Prospective Cohort Study (Preprint) DOI Creative Commons
Matthew Halma

Опубликована: Дек. 19, 2024

BACKGROUND Research efforts focusing on long covid have so far produced insights into the dysregulation of body processes. Development therapeutics has been limited to a few options which largely panned out. However, research work found some useful relationships between different diseases, and one important finding lends itself subsequent therapeutic are metabolic discoveries in patients. OBJECTIVE This study aims determine effective treatment for patients presenting with post vaccination syndrome, find biomarkers most predictive disease severity. METHODS Patients syndrome will be tested at baseline their general health (PAC-19QoL inventory, 6 Minute Walk Test Heart Rate Variability), prevalence spike protein, inflammatory markers (High sensitivity C-reactive Tumour necrosis factor alpha, IL-6, Antinuclear Antibody), as well coagulation (Von Willebrand Factor D-Dimer), (Acylcarnitine profile, free fatty acids, Hemoglobin A1c, β-Hydroxybutyrate, uric acid, amino acid panel, oxidation percentage, post-exercise lactate). also asked get commercial whole genome sequence identify risk loci vaccine injury or any interactions protocols. take combined nutraceutical supplement daily three months. Biomarker measurements taken interim after months assess non-inferiority control group. RESULTS is trial protocol, results analyzed see if there difference parameters follow up performed 1.5 trial, 3 following protocol. CONCLUSIONS The novel entity ‘long vax’, shares similar etiology features Covid, class protein related diseases (SPRD), high priority addresses an underserved patient population. While suggested levels evidence, from mechanistic hypothesis, vitro data, clinical trials conditions (acute Covid-19 infection), very exist vax. Our evaluate effectiveness protocol CLINICALTRIAL registered clinicaltrials.gov.

Язык: Английский

Процитировано

0